SCHEMBL304106

SCHEMBL304106

CNC(=O)c1cccc(N(Cc2ccc(Cl)cc2)S(=O)(=O)c2cn(C)cn2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
LMNA P02545 4/20 0.41
POLB P06746 1/20 0.41
NR1H2 P55055 1/20 0.40
NR1H3 Q13133 1/20 0.40
TP53 P04637 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TSHR P16473 1/20 0.39
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39
MAPT P10636 3/20 0.38
OXTR P30559 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
TRPM8 Q7Z2W7 1/20 0.38
YTHDC1 Q96MU7 1/20 0.38
SCN9A Q15858 1/20 0.38
GRM2 Q14416 1/20 0.38
NR4A2 P43354 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3378381 0.91 MEN1 (0.42) MEN1KMT2ALMNAPOLBNR1H2
SCHEMBL303353 0.90 LMNA (0.43) MEN1KMT2ALMNAPOLBNR1H2
SCHEMBL2211492 0.90 MEN1 (0.53) MEN1KMT2ALMNAPOLBNR1H2
SCHEMBL302166 0.89 MEN1 (0.44) MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL3378801 0.88 PIK3CG (0.43) MEN1KMT2ALMNAPOLBOXTR
SCHEMBL303633 0.87 MEN1 (0.47) MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL303898 0.87 MEN1 (0.49) MEN1KMT2ASMN1; SMN2ALDH1A1GAA
SCHEMBL18487091 0.85 LMNA (0.45) MEN1KMT2ALMNAPOLBNR1H2
SCHEMBL302499 0.85 PIK3CG (0.41) MEN1KMT2ALMNAMAPTOXTR
SCHEMBL3376298 0.85 FNTA (0.48) MEN1KMT2ALMNAPOLBNR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP claimed
US-8673901-B2 Potassium channel blockers XENTION LIMITED (GB) 2014-03-18 US claimed
JP-2012500836-A 2012-01-12 JP claimed
EP-2342177-A1 NOVEL POTASSIUM CHANNEL BLOCKERS Xention Limited (GB) 2011-07-13 EP claimed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP disclosed
EP-2342177-A1 NOVEL POTASSIUM CHANNEL BLOCKERS Xention Limited (GB) 2011-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087428-A1 Novel Potassium Channel Blockers HCN4, SCN2B, KCNH2 MEN1 2747/4885KMT2A 1511/4885LMNA 2145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.